8-K: Butterfly Network Reports Q3 2025 Growth, Record Low Cash Burn

Butterfly Network reports 5% YoY revenue growth and record low cash burn in Q3 2025, reaffirming full-year revenue guidance despite a significant inventory write-down.

Summary

• Total revenue for Q3 2025 was $21.5 million, representing a 5% year-over-year growth from $20.6 million in Q3 2024.
• Quarterly cash burn was reduced to a new record low of $3.9 million.
• Full-year revenue guidance was reaffirmed at $91 million to $95 million, projecting approximately 13% growth.
• Adjusted EBITDA loss guidance was narrowed to $32 million $35 million.
• GAAP gross loss was $3.8 million, compared to a gross profit of $12.2 million in the prior year period, primarily due to a $17.4 million write-down of excess and obsolete inventory.
• Adjusted gross profit increased to $13.7 million from $12.3 million in the prior year, with adjusted gross margin rising to 63.9% from 60.0%.
• Net loss for the quarter was $34.0 million, compared to $16.9 million in the prior year period.
• Adjusted EBITDA loss improved to $8.1 million from $8.4 million in the prior year period.
• Adjusted EPS was $(0.04), an improvement from $(0.05) in the prior year period.
• Cash and cash equivalents stood at $144.2 million as of September 30, 2025.
• A six-month quality-improvement study published in JAMA found that integrating Butterfly's Auto B-line Counter shortened hospital stays, saving 246 bed-days and $751,537 in direct costs.
• Achieved ISO 27001 certification and additional international security certifications for its cloud platform.
• HeartFocus by DESKi became the first FDA-cleared third-party app to launch on Butterfly Garden.
• Launched an AI-powered Gestational Age Calculator in Malawi and Uganda, with U.S. FDA submission pending.
• Completed development of Butterfly's P5.1 chip and initiated development of the sixth-generation Apollo AI chip.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company demonstrated revenue growth, improved adjusted financial metrics, and significant strategic and technological advancements, the substantial GAAP gross loss and increased net loss driven by a large inventory write-down temper the overall positive outlook. The reaffirmed guidance provides a degree of stability and confidence in future performance.

Positives

• Delivered 5% year-over-year revenue growth, reaching $21.5 million in Q3 2025.
• Achieved a new record low for quarterly cash usage, reducing cash burn to $3.9 million.
• Adjusted gross margin increased to 63.9% from 60.0% in the prior year period, driven by higher average selling prices and reduced software amortization costs.
• Adjusted EBITDA loss improved to $8.1 million from $8.4 million in the prior year period.
• Adjusted EPS improved to $(0.04) from $(0.05) in the prior year period.
• Reaffirmed full-year revenue guidance and narrowed adjusted EBITDA guidance, indicating confidence in future performance.
• A clinical study published in JAMA demonstrated that Butterfly's Auto B-line Counter saved 246 hospital bed-days and $751,537 in direct costs.
• Achieved ISO 27001 certification and other international security accreditations, enhancing global scalability and trust.
• Launched HeartFocus by DESKi, the first FDA-cleared third-party app on Butterfly Garden, expanding AI-guided echo exams.
• Introduced an AI-powered Gestational Age Calculator for global maternal health in Malawi and Uganda, with FDA review pending.
• Completed development of the P5.1 chip and initiated development of the Apollo AI chip, advancing technology leadership and future platform scalability.

Negatives

• Reported a GAAP gross loss of $3.8 million in Q3 2025, a significant decline from a gross profit of $12.2 million in Q3 2024.
• GAAP gross margin decreased substantially to (17.5)% from 59.5% in the prior year period.
• Net loss increased to $34.0 million in Q3 2025, compared to $16.9 million in Q3 2024.
• A $17.4 million write-down of excess and obsolete inventory was recognized during the quarter, impacting GAAP gross profit and margin.
• Operating expenses increased by 6% to $31.4 million from $29.5 million in the prior year period.

Risks

• Ability to grow and manage growth effectively.
• Success, cost, and timing of product and service development activities, including Compass AI, P5.1 chip, and Apollo AI chip.
• The degree to which products and services are accepted by healthcare practitioners and patients for their approved uses.
• Ability to obtain and maintain regulatory approval for products, such as the pending FDA review for the AI-powered Gestational Age Calculator.
• Ability to compete with other companies in the ultrasound imaging device market, many of which have greater financial and marketing resources.
• Changes in applicable laws or regulations.
• The size and growth potential of the markets for products and services, and the ability to serve those markets.
• The pricing of products and services, and reimbursement for medical procedures conducted using them.
• Estimates regarding expenses, revenue, capital requirements, and needs for additional financing.
• Ability to protect or enforce intellectual property rights.
• Ability to maintain the listing of Class A common stock on the New York Stock Exchange.

Future Outlook

The company reaffirmed its full-year revenue guidance of $91 million to $95 million, projecting approximately 13% growth, and narrowed its adjusted EBITDA loss guidance to $32 million $35 million. Management anticipates continued momentum through advancements in AI, strengthening enterprise readiness, and pushing forward on technology milestones such as the Compass AI launch, P5.1 chip moving to production, and the initiation of Apollo AI chip development, aiming to unlock the full value of Butterfly as a platform solution.

Management Comments

• "We view this quarter as a period of foundational progress for Butterfly. Even in a seasonally softer period, we delivered growth on top of last year's record third quarter growth, while continuing to reduce our use of cash." Joseph DeVivo, President, Chief Executive Officer and Chairman.
• "We stayed on the offense – advancing AI, strengthening enterprise readiness, and pushing forward on technology milestones that will shape our future. Our pipeline is expanding, and we believe we’re seeing the early signs of momentum returning." Joseph DeVivo.
• "We continue to emphasize that our strategy is about more than selling devices – it’s about changing how ultrasound is delivered and scaled. With Compass AI on the horizon, P5.1 chip moving to production, our Apollo AI chip initiating development, and our strategic initiatives taking shape, we’re unlocking the full value of Butterfly as a platform solution. This is how we lead the next chapter of ultrasound." Joseph DeVivo.

Industry Context

Butterfly Network operates in the rapidly evolving digital health and medical imaging sector, specializing in portable, semiconductor-based ultrasound technology. The company is positioned at the forefront of the point-of-care ultrasound (POCUS) market, leveraging AI and miniaturization to democratize healthcare by making imaging more affordable and accessible. Its focus on platform solutions, integrating advanced hardware, intelligent software, and AI, aligns with broader industry trends towards integrated, data-driven healthcare solutions and remote diagnostics, aiming to disrupt traditional ultrasound markets and address critical global healthcare challenges.

Comparison to Industry Standards

• Butterfly iQ3 earned 'Best Medical Technology' at the 2024 Prix Galien USA Awards, a prestigious honor, indicating high recognition within the healthcare industry.
• The company's innovations have been recognized by Fierce 50, TIME's Best Inventions, and Fast Company's World Changing Ideas, highlighting its leadership in technological advancement.
• The proprietary Ultrasound-on-Chip semiconductor technology provides a unique competitive advantage in the medical imaging market, differentiating it from traditional cart-based or less integrated portable systems.
• A six-month quality-improvement study published in JAMA demonstrated that Butterfly's Auto B-line Counter shortened hospital stays, saving 246 bed-days and $751,537 in direct costs, providing a strong benchmark for cost-effectiveness and clinical utility in hospital settings.
• The completion of the P5.1 chip development and initiation of the Apollo AI chip development for powerful edge AI capabilities demonstrate a commitment to pushing the boundaries of portable ultrasound technology, aiming for future platform scalability and advanced AI integration.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experience mixed impact with revenue growth and improved adjusted metrics offset by a significant GAAP gross loss and increased net loss due to an inventory write-down. Reaffirmed guidance offers some stability.
• Customers (Healthcare Practitioners/Hospitals): Benefit from new clinical validation demonstrating cost savings and improved patient outcomes, expanded AI-guided applications on Butterfly Garden, and enhanced security of the cloud platform.
• Employees: Continued innovation in AI and chip development, along with strategic advancements, suggest a forward-looking company with potential for growth and development opportunities.
• Suppliers/Partners: Ongoing development of new chip technologies (P5.1, Apollo AI) and expansion of the Butterfly Garden platform indicate continued demand for components and collaboration opportunities.

Next Steps

• Launch of Compass AI software.
• P5.1 chip moving to production.
• Apollo AI chip development for powerful edge AI capabilities and future platform scalability.
• Continued expansion of the Butterfly Garden platform with third-party applications.
• U.S. FDA review and potential clearance for the AI-powered Gestational Age Calculator.

Key Dates

Recommendation

The company demonstrated revenue growth and improved adjusted profitability metrics, alongside significant strategic and technological advancements. However, the substantial GAAP gross loss and increased net loss, primarily due to a large inventory write-down, introduce a notable caution. While the reaffirmed full-year guidance provides some stability, the mixed financial performance suggests a 'Hold' position until there is clearer evidence of sustained GAAP profitability and resolution of inventory issues. The long-term potential from AI and chip development is promising, but current financial results warrant a cautious approach.

Keywords

Ultrasound, Digital Health, Medical Imaging, Semiconductor, AI, Portable Ultrasound, POCUS, Butterfly iQ, BFLY, Healthcare Technology, Medical Devices, Q3 2025 Earnings, Financial Results